펄스장 절제술 시장 기회, 성장 촉진요인, 업계 동향 분석 및 예측(2026-2035년)

The Global Pulsed Field Ablation Market was valued at USD 2.2 billion in 2025 and is estimated to grow at a CAGR of 23.7% to reach USD 19.3 billion by 2035.

The market is experiencing rapid growth due to the increasing burden of cardiac arrhythmias, rising demand for minimally invasive treatment approaches, and growing adoption of advanced ablation technologies that offer improved safety and procedural outcomes. Pulsed field ablation (PFA) is an innovative cardiac treatment technology that uses high-voltage electrical energy to selectively target abnormal heart tissue through irreversible electroporation (IRE), allowing tissue modification without relying on heat-based mechanisms. This non-thermal approach supports precise treatment delivery while reducing the likelihood of injury to nearby sensitive anatomical structures. The increasing acceptance of catheter-based procedures, improvements in electrophysiology technologies, expanding availability of specialized cardiac care infrastructure, and rising focus on safer therapeutic options are contributing to market growth. The growing prevalence of cardiovascular conditions, including atrial fibrillation and other rhythm disorders, is further increasing the need for advanced ablation solutions. As healthcare providers continue prioritizing effective rhythm management strategies, the adoption of pulsed field ablation technologies is expected to accelerate significantly during the forecast period.

The catheter segment is expected to reach USD 12.6 billion by 2035. The segment's strong growth is supported by the increasing use of PFA procedures for managing cardiac arrhythmias, particularly atrial fibrillation. As the primary device responsible for delivering electrical energy to targeted cardiac tissue, PFA catheters play a vital role in achieving accurate and efficient ablation outcomes, making them a critical component of the overall treatment system.

The hospitals segment held 43.81% share in 2025. Hospitals remain the primary end users due to their access to advanced electrophysiology facilities, specialized medical professionals, and comprehensive infrastructure required for complex catheter-based procedures. The availability of advanced cardiac mapping technologies, imaging systems, and experienced electrophysiology teams enables hospitals to serve as major treatment centers for atrial fibrillation and other cardiac rhythm conditions.

U.S. Pulsed Field Ablation Market generated USD 1.2 billion in 2025. The United States represents a major market for pulsed field ablation technologies due to the high prevalence of cardiac arrhythmias, particularly atrial fibrillation. The increasing incidence of these conditions, supported by an aging population and the growing occurrence of related health risk factors, continues to create demand for advanced rhythm management solutions. Healthcare providers are increasingly adopting innovative ablation technologies to address the rising cardiovascular disease burden and improve patient outcomes.

Major companies operating in the global pulsed field ablation market include Medtronic, Abbott, Boston Scientific, Johnson & Johnson, Biotronik, Kardium, Pulsecare Medical, and Sichuan Jinjiang Electronics. Companies operating in the pulsed field ablation market are strengthening their competitive position by investing in advanced technology development, expanding product portfolios, and improving catheter-based ablation solutions. Market participants are focusing on enhancing treatment precision, procedural efficiency, device safety, and clinical performance through continuous research and innovation. Strategic collaborations with healthcare institutions, research organizations, and medical professionals are helping companies accelerate product development and expand clinical adoption. Businesses are also increasing investments in regulatory approvals, manufacturing capabilities, and global distribution networks to improve market accessibility. Companies are prioritizing clinical studies, technology improvements, and physician training programs to support wider acceptance of PFA procedures.

Table of Contents

Chapter 1 Research Methodology

• 1.1 Research approach
• 1.2 Quality commitments
  • 1.2.1 GMI AI policy & data integrity commitment
    • 1.2.1.1 Source consistency protocol
• 1.3 Research trail & confidence scoring
  • 1.3.1 Research trail components
  • 1.3.2 Scoring components
• 1.4 Data collection
  • 1.4.1 Partial list of primary sources
• 1.5 Data mining sources
  • 1.5.1 Paid sources
    • 1.5.1.1 Sources, by region
• 1.6 Base estimates and calculations
  • 1.6.1 Base year calculation for any one approach
• 1.7 Forecast model
  • 1.7.1 Quantified market impact analysis
    • 1.7.1.1 Mathematical impact of growth parameters on forecast
• 1.8 Research transparency addendum
  • 1.8.1 Source attribution framework
  • 1.8.2 Quality assurance metrics
  • 1.8.3 Our commitment to trust

Chapter 2 Executive Summary

• 2.1 Industry 360° synopsis
• 2.2 Key market trends
  • 2.2.1 Regional trends
  • 2.2.2 Product type trends
  • 2.2.3 End use trends
• 2.3 CXO perspectives: Strategic imperatives

Chapter 3 Industry Insights

• 3.1 Industry ecosystem analysis
• 3.2 Industry impact forces
  • 3.2.1 Growth drivers
    • 3.2.1.1 Increasing prevalence of atrial fibrillation and cardiac arrhythmias
    • 3.2.1.2 Growing demand for minimally invasive procedures
    • 3.2.1.3 Advancements in PFA technology
    • 3.2.1.4 Faster procedure times and reduced complications compared to thermal ablation
  • 3.2.2 Industry pitfalls and challenges
    • 3.2.2.1 Limited availability of skilled electrophysiologists
    • 3.2.2.2 High capital cost of PFA systems
  • 3.2.3 Market opportunities
    • 3.2.3.1 Expansion beyond atrial fibrillation into broader applications
• 3.3 Growth potential analysis
• 3.4 Regulatory landscape (Driven by primary research)
• 3.5 Technology landscape
  • 3.5.1 Current technological trends
  • 3.5.2 Emerging technologies
• 3.6 Pricing analysis (Driven by primary research)
• 3.7 Future market trends
• 3.8 Porter's analysis
• 3.9 PESTEL analysis
• 3.10 Impact of AI and Generative AI on the market (Driven by primary research)
• 3.11 Value chain analysis (Driven by primary research)
• 3.12 Pipeline analysis
• 3.13 Reimbursement scenario
• 3.14 The 2024-2026 PFA breakout - reshaped cardiac EP landscape
• 3.15 Safety profile comparison - PFA vs. Radiofrequency Ablation vs. Cryoablation

Chapter 4 Competitive Landscape, 2025

• 4.1 Introduction
• 4.2 Company matrix analysis
• 4.3 Company market share analysis (Driven by primary research)
  • 4.3.1 Global
  • 4.3.2 U.S.
  • 4.3.3 Spain
  • 4.3.4 Italy
  • 4.3.5 Japan
  • 4.3.6 Rest of the World
• 4.4 Competitive positioning matrix
• 4.5 Competitive analysis of major market players
• 4.6 Key developments
  • 4.6.1 Mergers & acquisitions
  • 4.6.2 Partnerships & collaborations
  • 4.6.3 New product launches
  • 4.6.4 Expansion plans

Chapter 5 Market Estimates and Forecast, By Product Type, 2022 - 2035 ($ Mn)

• 5.1 Key trends
• 5.2 Generators
• 5.3 Catheters
• 5.4 Accessory devices

Chapter 6 Market Estimates and Forecast, By End Use, 2022 - 2035 ($ Mn)

• 6.1 Key trends
• 6.2 Hospitals
• 6.3 Cardiac catheterization labs
• 6.4 Ambulatory surgical centers
• 6.5 Other end users

Chapter 7 Market Estimates and Forecast, By Region, 2022 - 2035 ($ Mn)

• 7.1 Key trends
• 7.2 U.S.
• 7.3 Spain
• 7.4 Italy
• 7.5 Japan
• 7.6 RoW

Chapter 8 Company Profiles

• 8.1 Abbott
• 8.2 Biotronik
• 8.3 Boston Scientific
• 8.4 Johnson & Johnson
• 8.5 Kardium
• 8.6 Medtronic
• 8.7 Pulsecare Medical
• 8.8 Sichuan Jinjiang Electronics